What's Next In Pharmaceutical R&D? A Conversation With Upperton's Director Of Pharmaceutical Sciences

The pharmaceutical R&D landscape is rapidly evolving, with significant attention focused on novel drug delivery systems like pulmonary and nasal routes. Soft mist inhalers (SMIs) are gaining interest for their ability to deliver medication as a slow-moving aerosol, potentially improving lung deposition and patient adherence compared to traditional nebulizers. The global pulmonary and nasal drug delivery markets are projected for substantial growth, driven by technology gains, demographic shifts, and the move toward at-home respiratory care.

Another persistent challenge in formulation science is overcoming poor solubility for compounds, particularly those categorized as Biopharmaceutics Classification System (BCS) Class II and IV, which represent 70–90% of current drug candidates. Techniques such as amorphous solid dispersions, lipid-based formulations, and the production of nanosuspensions via methods like microfluidics are critical for improving bioavailability.

For biotech firms, successful R&D partnerships go beyond bench science, requiring flexibility, agility, and the ability to align formulation development with the client's broader strategic goals. Trust and transparency are essential non-negotiables, especially when navigating risks and challenges with early-stage compounds. Delve into the latest trends and hurdles shaping drug development.